Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Summary

The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.

Timeline

Start

2015-09-01

Primary completion

2017-07-21

Completion

2017-07-21

Outcome

Missed primary endpoint

registry p = 0.073; SPCD Weighted OLS z-statistic -1.79 (95% CI -3.75 to 0.17); Mixed Models Analysis NCT02477670 ↗

Drugs

Indications